阿托西班联合盐酸利托君在IVF/ICSI新鲜周期胚胎移植中的应用评价(1)
[摘要] 目的 探討抑制子宫收缩药物阿托西班联合盐酸利托君在IVF/ICSI新鲜周期胚胎移植中的应用价值。方法 方便选择2014年11月—2016年11月期间在该院生殖中心行IVF/ICSI-ET助孕的新鲜周期移植患者278例为研究对象，剔除年龄>38岁、扳机日子宫内膜厚度<7 mm者及反复移植失败者。将所有研究对象随机分为4组：A组78例，阿托西班联合盐酸利托君组(移植前30 min静推阿托西班0.9 mL)；B组72例，阿托西班组(移植前30 min静推阿托西班0.9 mL，移植后30 min开始每8小时一次舌下含服盐酸利托君10mg至移植后第3天)；C组64例，盐酸利托君组(移植前30分钟舌下含服盐酸利托君10 mg，移植后30 min开始每8 h一次舌下含服盐酸利托君10 mg至移植后第3天)；D组64例，移植前未用抑制子宫收缩药物组(移植前后均未用抑制子宫收缩药物)。比较4组患者移植后的妊娠结局。结果 A组、B组、C组和D组患者HCG阳性率分别为66.67%、62.50%、59.37%和57.81%；4组患者着床率分别为34.67%、32.84%、29.51%和30.51%；4组患者临床妊娠率分别为64.10%、61.11%、54.69%和56.25%。A组HCG阳性率、着床率及临床妊娠率明显高于B组、C组及D组(P< 0.05)。B组HCG阳性率、着床率及临床妊娠率明显高于C组和D组(P< 0.05)。C组与D组比较，HCG阳性率、着床率及临床妊娠率差异无统计学意义(P>0.05)。结论 阿托西班联合盐酸利托君可作为提高HCG阳性率及胚胎着床率从而提高IVF-ET助孕成功率的重要手段之一。
[关键词] 阿托西班；盐酸利托君；HCG阳性率；临床妊娠率
[中图分类号] R714 [文献标识码] A [文章编号] 1674-0742(2017)05(c)-0022-04
[Abstract] Objective To discuss the application value of atosiban and ritodrine hydrochloride in the transplantation of embryo in fresh IVF/ICSI cycle. Methods 278 cases of fresh cycle transplantation patients with IVF/ICSI-ET promoting gestation in the reproductive center in our hospital form November 2014 to November 2016 were convenient selected and the patients aged above 38 years， whose endometrial thickness < 7 mm and repeated transplantation failure were excluded， and all patients were randomly divided into four groups， the group A with 78 cases were treated with atosiban and ritodrine hydrochloride (intravenous injection of 0.9 mL atosiban in 30 min before transplantation)， the group B with 72 cases (intravenous injection of 0.9 mL atosiban in 30 min before transplantation， sublingual of ritodrine hydrochloride once every 8 hours from 30 min of transplantation to 3 d after transplantation)， the group C with 64 cases (sublingual of 10 mgritodrine hydrochloride in 30 min after transplantation， sublingual of 10 mgritodrine hydrochloride once every 8 hours from the 30 min of transportation to 3 d after transplantation)， the group D with 64 cases did not use the drugs of suppressing uterine contraction before and after the transportation， and the pregnant outcome after transplantation was compared between the four groups. Results The HCG positive rate in the group A， group B， group C and group C was respectively 66.67%，62.50%，59.37%， 57.81%， and the implantation rate of the group A， group B， group C and group C was respectively 34.67%，32.84%，29.51%， 30.51%， the clinical pregnant rate of the four groups was 64.10%，61.11%，54.69%， 56.25%， and the HCG positive rate， implantation rate and clinical pregnant rate in the group A were obviously higher than those in the group B， C and D(P<0.05)， and these factors in the group B were obviously higher than those in the group C and group D(P<0.05)， and there were no obvious differences in these factors between the group C and group D(P>0.05). Conclusion Atosiban and ritodrine hydrochloride can be one of the important means of improving the HCG positive rate and embryo implantation rate thus improving the success rate of IVF-ET promoting gestation., http://www.100md.com(李宝香 吴仕元 廖美霞 范晓波)
[关键词] 阿托西班；盐酸利托君；HCG阳性率；临床妊娠率
[中图分类号] R714 [文献标识码] A [文章编号] 1674-0742(2017)05(c)-0022-04
[Abstract] Objective To discuss the application value of atosiban and ritodrine hydrochloride in the transplantation of embryo in fresh IVF/ICSI cycle. Methods 278 cases of fresh cycle transplantation patients with IVF/ICSI-ET promoting gestation in the reproductive center in our hospital form November 2014 to November 2016 were convenient selected and the patients aged above 38 years， whose endometrial thickness < 7 mm and repeated transplantation failure were excluded， and all patients were randomly divided into four groups， the group A with 78 cases were treated with atosiban and ritodrine hydrochloride (intravenous injection of 0.9 mL atosiban in 30 min before transplantation)， the group B with 72 cases (intravenous injection of 0.9 mL atosiban in 30 min before transplantation， sublingual of ritodrine hydrochloride once every 8 hours from 30 min of transplantation to 3 d after transplantation)， the group C with 64 cases (sublingual of 10 mgritodrine hydrochloride in 30 min after transplantation， sublingual of 10 mgritodrine hydrochloride once every 8 hours from the 30 min of transportation to 3 d after transplantation)， the group D with 64 cases did not use the drugs of suppressing uterine contraction before and after the transportation， and the pregnant outcome after transplantation was compared between the four groups. Results The HCG positive rate in the group A， group B， group C and group C was respectively 66.67%，62.50%，59.37%， 57.81%， and the implantation rate of the group A， group B， group C and group C was respectively 34.67%，32.84%，29.51%， 30.51%， the clinical pregnant rate of the four groups was 64.10%，61.11%，54.69%， 56.25%， and the HCG positive rate， implantation rate and clinical pregnant rate in the group A were obviously higher than those in the group B， C and D(P<0.05)， and these factors in the group B were obviously higher than those in the group C and group D(P<0.05)， and there were no obvious differences in these factors between the group C and group D(P>0.05). Conclusion Atosiban and ritodrine hydrochloride can be one of the important means of improving the HCG positive rate and embryo implantation rate thus improving the success rate of IVF-ET promoting gestation., http://www.100md.com(李宝香 吴仕元 廖美霞 范晓波)